Scarica l'app Stockscreener
7.41
0.27%
-0.02
Dopo l'orario di chiusura:
7.28
-0.13
-1.75%
Precedente Chiudi:
$7.43
Aprire:
$7.51
Volume 24 ore:
585.12K
Relative Volume:
0.75
Capitalizzazione di mercato:
$484.51M
Reddito:
$89.40M
Utile/perdita netta:
$-221.30M
Rapporto P/E:
-2.2755
EPS:
-3.2564
Flusso di cassa netto:
$-256.90M
1 W Prestazione:
-2.37%
1M Prestazione:
-22.73%
6M Prestazione:
-31.71%
1 anno Prestazione:
-20.06%
Intervallo 1D:
$7.30
$7.52
Intervallo di 1 settimana:
$7.30
$8.04
Portata 52W:
$6.97
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.41 | 496.28M | 89.40M | -221.30M | -256.90M | -3.2564 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-10-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-09-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Arvinas to present ARV-102 Parkinson’s data at MDS congress By Investing.com - Investing.com Canada
Arvinas to Present Novel Biomarker Data from the Phase 1 - GlobeNewswire
252,939 Shares in Arvinas, Inc. $ARVN Acquired by Bank of America Corp DE - MarketBeat
Arvinas (NASDAQ:ARVN) Shares Climb 6.3%What's Next? - MarketBeat
Arvinas, Inc. (ARVN) stock price, news, quote and history - uk.finance.yahoo.com
Price-Driven Insight from (ARVN) for Rule-Based Strategy - Stock Traders Daily
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arvinas, Inc. (ARVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arvinas enters immuno-oncology with HPK1 PROTAC degrader in Phase I/II trial - AllSci
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Arvinas doses first patient in ARV-6723 cancer trial - Investing.com
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical - GlobeNewswire
Form 144 ARVINAS For: 27 September By Investing.com - Investing.com Australia
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
ARVN News | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Arvinas Q2 2026 Earnings Call Transcript - Benzinga
Arvinas (NASDAQ: ARVN) director plans stock sale under SEC resale rule - Stock Titan
ARVN Q2 2026 Earnings: EPS Swings to $2.58, Beating Estimates by a Wide MarginEarnings Outlook Update - dars.gov.et
Arvinas, Inc. (ARVN) Stock Analysis: Uncovering a Potential 67.61% Upside in the Biotech Sector - DirectorsTalk Interviews
Arvinas, Inc. $ARVN Shares Purchased by Squarepoint Ops LLC - MarketBeat
Piper Sandler Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Arvinas at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline takes center stage - investing.com
Former Arvinas (NASDAQ: ARVN) officer plans new stock sale - Stock Titan
(ARVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod - Yahoo Finance
Arvinas at Wells Fargo conference: pipeline nears key data By Investing.com - Investing.com South Africa
Arvinas (ARVN) Stock Price, News & Analysis - Stock Titan
Former Arvinas (NASDAQ: ARVN) officer lines up new stock sale after recent trades - Stock Titan
Arvinas to Participate in Upcoming Investor Conferences - Yahoo Finance
Arvinas Inc. (ARVN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Arvinas Inc. (ARVN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
ARVN Q2 2026 Earnings: EPS of $2.58 Blows Past Consensus; Stock Slips 0.65%Tax Rate Impact - vinanet.vn
The Technical Signals Behind (ARVN) That Institutions Follow - Stock Traders Daily
Arvinas: Veppanu Approval Underlines Degrader Platform PromiseI'm Bullish (NASDAQ:ARVN) - Seeking Alpha
Arvinas (ARVN) Momentum: Gains 3.77% to Reach $9.37 in the Current Update; Chart Watch - dars.gov.et
Arvinas (ARVN) Quarterly Results: EPS Lands Above Forecast for the Current Session; Trading Response: Shares Finish 4.54% Higher at the ClosePerformance Review - vinanet.vn
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Arvinas (ARVN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations at the Close; Price Reaction: Shares Move 0.22% Up in the Current UpdateEPS Growth Report - dars.gov.et
142,214 Shares in Arvinas, Inc. $ARVN Purchased by GSA Capital Partners LLP - MarketBeat
Arvinas Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Arvinas (ARVN) Holds Ground Near $8.97 as Biotech Stock Tests Key Support ZoneConversion Trade - vinanet.vn
Arvinas Inc (ARVN) Stock Price, Quote, News & History - Benzinga
D. E. Shaw adjusts Arvinas (ARVN) stake as one entity falls below 5% - Stock Titan
Arvinas (ARVN) Q2 2026 Earnings Call Transcript - AOL.com
Morgan Stanley Maintains Arvinas(ARVN.US) With Hold Rating, Maintains Target Price $10 - Moomoo
Enterprise value to EBITDA forward of Arvinas, Inc. – NASDAQ:ARVN - TradingView
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):